Skip to main content
Midas Edge

Beam Therapeutics Inc.

For the period ended Sep 30, 2026. Filed Nov 3, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 3, 2026

BEAM$25.15-6.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share amounts)

Common Stock · AdditionalPaid-in · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’
SharesAmountCapitalIncome (Loss)DeficitEquity
Balance at December 31, 202483,633,069$836$2,298,661$679$(1,566,631)$733,545
Cumulative effect of adoption of ASU 2025-07————5,4045,404
Purchase of common stock under ESPP90,43611,500——1,501
Issuance of common stock and pre-funded warrants, net of issuance costs of $30.8 million16,151,686162470,316——470,478
Vesting of restricted common stock607,1966(6)———
Stock-based compensation——26,682——26,682
Exercise of common stock options74,7071718——719
Other comprehensive income (loss)———(519)—(519)
Net loss————(108,330)(108,330)
Balance at March 31, 2025100,557,094$1,006$2,797,871$160$(1,669,557)$1,129,480
Issuance of common stock and pre-funded warrants, net of issuance costs of $30.8 million——(4)——(4)
Vesting of restricted common stock81,1631(1)———
Stock-based compensation——24,367——24,367
Exercise of common stock options120,49111,754——1,755
Other comprehensive income (loss)———(150)—(150)
Net loss————(102,138)(102,138)
Balance at June 30, 2025100,758,748$1,008$2,823,987$10$(1,771,695)$1,053,310
Purchase of common stock under ESPP84,27211,262——1,263
Vesting of restricted common stock95,5801(1)———
Stock-based compensation——22,747——22,747
Issuance of common stock for acquisition403,12846,711——6,715
Exercise of common stock options18,037—412——412
Other comprehensive income (loss)———780—780
Net loss————(112,571)(112,571)
Balance at September 30, 2025101,359,765$1,014$2,855,118$790$(1,884,266)$972,656

Condensed Consolidated Statements of Stockholders’ Equity - Continued

(in thousands, except share amounts)

Common Stock · AdditionalPaid-in · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’
SharesAmountCapitalIncome (Loss)DeficitEquity
Balance at December 31, 2025101,748,962$1,017$2,877,449$1,111$(1,641,219)$1,238,358
Purchase of common stock under ESPP74,51811,509——1,510
Vesting of restricted common stock720,6977(7)———
Stock-based compensation——19,044——19,044
Exercise of common stock options197,67122,023——2,025
Other comprehensive income (loss)———(2,181)—(2,181)
Net loss————(94,318)(94,318)
Balance at March 31, 2026102,741,848$1,027$2,900,018$(1,070)$(1,735,537)$1,164,438
Vesting of restricted common stock74,5781(1)———
Stock-based compensation——19,278——19,278
Exercise of common stock options448,21057,518——7,523
Other comprehensive income (loss)———(1,119)—(1,119)
Net loss————(122,678)(122,678)
Balance at June 30, 2026103,264,636$1,033$2,926,813$(2,189)$(1,858,215)$1,067,442
Purchase of common stock under ESPP66,47311,367——1,368
Vesting of restricted common stock71,724—————
Stock-based compensation——18,555——18,555
Exercise of common stock options40,402—959——959
Other comprehensive income (loss)———(1,245)—(1,245)
Net loss————(134,405)(134,405)
Balance at September 30, 2026103,443,235$1,034$2,947,694$(3,434)$(1,992,620)$952,674
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.